mRNA Therapeutics

Turning your own cells into the drug factory.

Instead of manufacturing a protein in a bioreactor, mRNA drugs deliver the instructions and let your cells make it. The breakthroughs were chemical: modified nucleosides that stop the immune system rejecting the message, an engineered cap for stability, and lipid nanoparticles (LNPs) to smuggle it into cells.

COVID vaccines were act one. The pipeline now reaches into cancer vaccines, protein-replacement and regenerative medicine. The edge is in the chemistry — better caps, longer-lasting message, targeted delivery. Poland's ExploRNA is chasing exactly that.

How it works in depth

An mRNA therapeutic does not deliver a protein drug directly. Instead it delivers a coded set of instructions, packaged inside a lipid nanoparticle (LNP), that your own cells read on the ribosome to manufacture the target protein in place. This is why the modality is described as turning your cells into the drug factory. The mRNA is typically engineered with modified nucleosides (such as N1-methylpseudouridine) and optimized untranslated regions and caps to evade innate immune sensors, raise translation, and tune how long the message persists. Because the product is transient and never enters the genome, there is no permanent genetic change, and the same manufacturing platform can be reprogrammed simply by swapping the coding sequence, enabling rapid, individualized design.

The field splits into three uses. Prophylactic vaccines express a pathogen antigen to prime immunity. Cancer immunotherapy encodes tumor neoantigens, sometimes individualized to each patient's sequenced tumor, to direct T cells against the cancer. Protein-replacement and in vivo therapeutics aim to make a missing or therapeutic protein inside the patient, for example a functional metabolic enzyme. A newer variant, self-amplifying RNA (saRNA), encodes a viral replicase so a small dose seeds many RNA copies, raising and prolonging expression at lower doses.

Where the field is in 2025-2026

Beyond COVID-19 and RSV, the frontier is oncology and rare disease. In February 2025 the European Commission approved KOSTAIVE (ARCT-154) from Arcturus and CSL, reportedly the first self-amplifying mRNA COVID-19 vaccine cleared in the EU, following earlier approval in Japan. The long-running CureVac patent litigation against Pfizer/BioNTech was settled in August 2025, with BioNTech subsequently moving to acquire CureVac, consolidating the European mRNA field.

Leading programs and players

Moderna and Merck co-develop intismeran autogene (mRNA-4157 / V940), an individualized neoantigen therapy. In the Phase 2b KEYNOTE-942 melanoma trial, combining it with KEYTRUDA (pembrolizumab) reportedly reduced the risk of recurrence or death by about 49% versus pembrolizumab alone, with that benefit sustained at five-year follow-up reported in January 2026; pivotal Phase 3 trials in adjuvant melanoma and NSCLC are enrolling. BioNTech, with Genentech/Roche, advances autogene cevumeran in resected pancreatic cancer (PDAC), where early-phase data showed durable neoantigen-specific T-cell responses correlating with delayed recurrence in responders, now in a larger Phase 2. Moderna's mRNA-3927 for propionic acidemia is an early in vivo protein-replacement program. Other players include Pfizer, GSK, Sanofi and Arcturus. The outlook hinges on whether individualized cancer vaccines confirm survival benefit in Phase 3 and on solving delivery beyond the liver and muscle.

FAQ

Are mRNA therapeutics only vaccines?

No. While COVID-19 and RSV vaccines are the best-known examples, mRNA is also being developed for individualized cancer immunotherapy (e.g., Moderna/Merck's intismeran autogene and BioNTech's autogene cevumeran) and for in vivo protein replacement in rare metabolic diseases such as Moderna's mRNA-3927 for propionic acidemia.

Can mRNA change your DNA?

No. mRNA stays in the cell's cytoplasm, is read by ribosomes to make a protein, and is then degraded. It does not enter the nucleus or integrate into the genome, so it does not alter your DNA.

What is an individualized or personalized mRNA cancer vaccine?

It is a therapy designed from a specific patient's sequenced tumor. Software predicts the patient's unique tumor mutations (neoantigens), and an mRNA encoding those targets is manufactured to train the immune system to attack that individual's cancer, often alongside a checkpoint inhibitor like pembrolizumab.

What is self-amplifying mRNA (saRNA)?

saRNA includes a viral replicase that copies the RNA inside the cell, so a smaller dose produces more and longer-lasting protein. Arcturus and CSL's KOSTAIVE, approved in the EU in February 2025, is reportedly the first self-amplifying mRNA COVID-19 vaccine authorized there.

Companies working on mRNA Therapeutics

Explore the interactive landscapes →